FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4321457608> ?p ?o ?g. }

• W4321457608 abstract "Novel antibody‒drug conjugates (ADC) have shown great efficacy in HER2-low advanced breast cancer. However, the clinical features of HER2-low disease still need to be clarified. The current study aims to evaluate the distribution and dynamic change in HER2 expression in patients with disease recurrence and the clinical outcome of those patients.Patients with pathologically diagnosed relapsed breast cancer between 2009 and 2018 were included. Samples were considered HER2-zero when the immunohistochemistry (IHC) score was 0, HER2-low when the IHC score was 1 + or 2 + with negative fluorescence in situ hybridization (FISH) results, and HER2-positive when the IHC score was 3 + or the FISH results were positive. Breast cancer-specific survival (BCSS) was compared among the three HER2 groups. Changes in HER2 status were also evaluated.A total of 247 patients were included. Among recurrent tumors, 53 (21.5%) were HER2-zero, 127 (51.4%) were HER2-low, and 67 (27.1%) were HER2-positive. The HER2-low subtype represented 68.1% of the HR-positive breast cancer group and 31.3% of the HR-negative group (P < 0.001). This three-group classification of HER2 status was prognostic in advanced breast cancer (P = 0.0011), with HER2-positive patients having the best clinical outcome after disease recurrence (P = 0.024), while only marginal survival advantages were observed in HER2-low patients versus HER2-zero patients (P = 0.051). In the subgroup analysis, the survival difference was observed only in patients with HR-negative recurrent tumors (P = 0.0006) or with distant metastasis (P = 0.0037). The overall discordance rate of HER2 status between primary and recurrent tumors was 38.1%, with 25 (49.0%) primary HER2-zero patients and 19 (26.8%) HER2-positive patients shifting to HER2-low at recurrence.Nearly half of the advanced breast cancer patients had HER2-low disease, which indicates a poorer prognosis than HER2-positive disease and marginally better outcomes than HER2-zero disease. During disease progression, one-fifth of tumors convert to HER2-low entities, and the corresponding patients may benefit from ADC treatment." @default.
• W4321457608 created "2023-02-22" @default.
• W4321457608 creator A5000005088 @default.
• W4321457608 creator A5020266322 @default.
• W4321457608 creator A5057638932 @default.
• W4321457608 creator A5066927624 @default.
• W4321457608 creator A5069069964 @default.
• W4321457608 creator A5072445958 @default.
• W4321457608 date "2023-02-21" @default.
• W4321457608 modified "2023-09-30" @default.
• W4321457608 title "Distribution, dynamic evolution, and clinical outcomes of patients with advanced breast cancer according to HER2 expression" @default.
• W4321457608 cites W1830854044 @default.
• W4321457608 cites W2022102157 @default.
• W4321457608 cites W2101979288 @default.
• W4321457608 cites W2130900820 @default.
• W4321457608 cites W2137763083 @default.
• W4321457608 cites W2141393790 @default.
• W4321457608 cites W2145257123 @default.
• W4321457608 cites W2156878255 @default.
• W4321457608 cites W2226378560 @default.
• W4321457608 cites W2228039186 @default.
• W4321457608 cites W2294307578 @default.
• W4321457608 cites W2399215084 @default.
• W4321457608 cites W2468868288 @default.
• W4321457608 cites W2560406314 @default.
• W4321457608 cites W2586629973 @default.
• W4321457608 cites W2771728402 @default.
• W4321457608 cites W2806209829 @default.
• W4321457608 cites W2894868352 @default.
• W4321457608 cites W2946663880 @default.
• W4321457608 cites W2953684910 @default.
• W4321457608 cites W2994917610 @default.
• W4321457608 cites W3005585857 @default.
• W4321457608 cites W3008591390 @default.
• W4321457608 cites W3018222852 @default.
• W4321457608 cites W3039297055 @default.
• W4321457608 cites W3042830787 @default.
• W4321457608 cites W3119128530 @default.
• W4321457608 cites W3130200855 @default.
• W4321457608 cites W3140415241 @default.
• W4321457608 cites W3162334759 @default.
• W4321457608 cites W3166066183 @default.
• W4321457608 cites W3179156059 @default.
• W4321457608 cites W3205002341 @default.
• W4321457608 cites W4286679813 @default.
• W4321457608 doi "https://doi.org/10.1186/s12885-023-10634-7" @default.
• W4321457608 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36810001" @default.
• W4321457608 hasPublicationYear "2023" @default.
• W4321457608 type Work @default.
• W4321457608 citedByCount "3" @default.
• W4321457608 countsByYear W43214576082023 @default.
• W4321457608 crossrefType "journal-article" @default.
• W4321457608 hasAuthorship W4321457608A5000005088 @default.
• W4321457608 hasAuthorship W4321457608A5020266322 @default.
• W4321457608 hasAuthorship W4321457608A5057638932 @default.
• W4321457608 hasAuthorship W4321457608A5066927624 @default.
• W4321457608 hasAuthorship W4321457608A5069069964 @default.
• W4321457608 hasAuthorship W4321457608A5072445958 @default.
• W4321457608 hasBestOaLocation W43214576081 @default.
• W4321457608 hasConcept C104317684 @default.
• W4321457608 hasConcept C121608353 @default.
• W4321457608 hasConcept C126322002 @default.
• W4321457608 hasConcept C143998085 @default.
• W4321457608 hasConcept C185592680 @default.
• W4321457608 hasConcept C204232928 @default.
• W4321457608 hasConcept C2777542201 @default.
• W4321457608 hasConcept C2779134260 @default.
• W4321457608 hasConcept C2779786085 @default.
• W4321457608 hasConcept C2780140570 @default.
• W4321457608 hasConcept C30481170 @default.
• W4321457608 hasConcept C530470458 @default.
• W4321457608 hasConcept C55493867 @default.
• W4321457608 hasConcept C71924100 @default.
• W4321457608 hasConceptScore W4321457608C104317684 @default.
• W4321457608 hasConceptScore W4321457608C121608353 @default.
• W4321457608 hasConceptScore W4321457608C126322002 @default.
• W4321457608 hasConceptScore W4321457608C143998085 @default.
• W4321457608 hasConceptScore W4321457608C185592680 @default.
• W4321457608 hasConceptScore W4321457608C204232928 @default.
• W4321457608 hasConceptScore W4321457608C2777542201 @default.
• W4321457608 hasConceptScore W4321457608C2779134260 @default.
• W4321457608 hasConceptScore W4321457608C2779786085 @default.
• W4321457608 hasConceptScore W4321457608C2780140570 @default.
• W4321457608 hasConceptScore W4321457608C30481170 @default.
• W4321457608 hasConceptScore W4321457608C530470458 @default.
• W4321457608 hasConceptScore W4321457608C55493867 @default.
• W4321457608 hasConceptScore W4321457608C71924100 @default.
• W4321457608 hasFunder F4320321001 @default.
• W4321457608 hasFunder F4320321885 @default.
• W4321457608 hasFunder F4320328346 @default.
• W4321457608 hasIssue "1" @default.
• W4321457608 hasLocation W43214576081 @default.
• W4321457608 hasLocation W43214576082 @default.
• W4321457608 hasLocation W43214576083 @default.
• W4321457608 hasOpenAccess W4321457608 @default.
• W4321457608 hasPrimaryLocation W43214576081 @default.
• W4321457608 hasRelatedWork W1722328147 @default.
• W4321457608 hasRelatedWork W1955147862 @default.
• W4321457608 hasRelatedWork W2029129343 @default.
• W4321457608 hasRelatedWork W2048357551 @default.

• next